Actiq News
Strong Sales at Cephalon: Fool by Numbers - Motley Fool
Cephalon's successful transition of its pain franchise to Fentora from Actiq ensured that sales ramped up smoothly. Strong top-line growth and a decline in ...
Cephalon's Earnings Surprise - Motley Fool
Paradoxically, Cephalon stated that one of the reasons for the higher earnings guidance was that its pain franchise drugs, Actiq and Fentora, ...
NEWSWEEK Media Lead Sheet/May 7, 2007 Issue (on newsstands Monday ... - PR-Inside.com (Pressemitteilung)
General Editor Mary Carmichael reports on a major controversy surrounding the use of Actiq, an FDA-approved medication for treating cancer pain, ...
Drugmaker Cephalon's profit soars - CNNMoney.com
Cephalon said Actiq had sales of $65.7 million in the quarter, down from $108.9 million in the previous quarter. Fentora sales reached $31.7 million. ...
UPDATE 2-Cephalon posts sharply higher 1st-qtr profit - Reuters
The company, which is working to transition patients from its older cancer pain medicine Actiq to its new Fentora, said Actiq had sales of $65.7 million, ...
Cephalon's 1st quarter beats forecasts - Philadelphia Inquirer
Cephalon said it was reaching out to doctors who had never prescribed its cancer-pain drug Actiq to tout its new Fentora. Actiq sales fell 44 percent to ...
Questions are raised over how a potent painkiller has been marketed. - Newsweek
May 7, 2007 issue - The fast-acting narcotic lollipop Actiq is FDA-approved for treating cancer pain, and cancer pain only. Patients are warned not to ...
Actiq RSS Feed